Immunic Aktie

0,9790 EUR +0,0820 EUR +9,14 %

14:04:07

MUN

1,11 USD -0,02 USD -1,78 %

16:32:38

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.91,52 Mio. EUR

Div. Rendite0,00%

WKNA2PHD4

ISINUS4525EP1011

SymbolIMUX

Immunic Aktien News

Sortieren:Datum Meistgelesen

04.10.23PR NewswireImmunic to Participate in Scientific Conferences in October

06.09.23PR NewswireImmunic to Participate in Industry and Investor Conferences in September

17.08.23PR NewswireImmunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

04.08.23finanzen.netImmunic hat die Zahlen zum jüngsten Quartal vorgelegt

03.08.23PR NewswireImmunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

01.08.23PR NewswireImmunic to Participate in Investor and Scientific Conferences in August

27.07.23PR NewswireImmunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

29.06.23PR NewswireImmunic to Participate in Scientific and Investor Conferences in July

30.05.23PR NewswireImmunic to Participate in Scientific and Investor Conferences in June

17.05.23PR NewswireImmunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

12.05.23finanzen.netImmunic stellte Quartalsergebnis zum abgelaufenen Jahresviertel vor

11.05.23PR NewswireImmunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

09.05.23PR NewswireImmunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update

06.05.23PR NewswireImmunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

04.05.23PR NewswireImmunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

27.04.23PR NewswireImmunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

26.04.23PR NewswireImmunic to Participate in Investor and Scientific Conferences in May

05.04.23PR NewswireImmunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

02.03.23PR NewswireImmunic to Participate in Investor and Scientific Conferences in March

24.02.23finanzen.netImmunic öffnete die Bücher zum abgelaufenen Quartal

23.02.23PR NewswireImmunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update

22.02.23PR NewswireImmunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

16.02.23PR NewswireImmunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update

09.02.23PR NewswireImmunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

25.01.23PR NewswireImmunic to Participate in Scientific and Investor Conferences in February

17.11.22PR NewswireImmunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

10.11.22PR NewswireImmunic to Participate in Investor and Scientific Conferences in November and December

04.11.22finanzen.netImmunic öffnete die Bücher zum abgelaufenen Quartal

03.11.22PR NewswireImmunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

27.10.22PR NewswireImmunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update

20.10.22PR NewswireImmunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

10.10.22PR NewswireImmunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing

04.10.22PR NewswireImmunic to Participate in Scientific and Industry Conferences in October

20.09.22PR NewswireImmunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

01.09.22PR NewswireImmunic, Inc. to Participate in Investor Conferences in September

16.08.22PR NewswireImmunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regenera...

05.08.22finanzen.netImmunic: Was beim Unternehmen in den jüngsten Büchern steht

04.08.22PR NewswireImmunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

02.08.22PR NewswireImmunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

28.07.22PR NewswireImmunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update

Immunic News

Immunic News: auf dieser Seite finden Sie alle Immunic News und Nachrichten zur Immunic Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Immunic News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Immunic News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.